Business Context and Reporting Period
This Form 8-K was filed by Platform Specialty Products Corporation on January 12, 2015. The filing serves as a voluntary disclosure of financial information and management discussion related to the proposed acquisition of Arysta LifeScience Limited ("Arysta") for approximately $3.51 billion. The report incorporates by reference Arysta's audited financial statements for fiscal years ended December 31, 2012 and 2013, and unaudited statements for the nine-month periods ended September 30, 2013 and 2014.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity within the body of the report. These metrics are contained in the attached exhibits (Exhibits 99.1 through 99.4) which are incorporated by reference. The filing does disclose the proposed transaction value of approximately $3.51 billion for the Arysta Acquisition.
Material Changes and Transactions
- Proposed Acquisition: Platform entered into a Share Purchase Agreement to acquire Arysta for approximately $3.51 billion, subject to customary closing conditions.
- Pro Forma Adjustments: The filing includes unaudited pro forma combined consolidated financial statements giving effect to the proposed Arysta Acquisition, the acquisition of the Chemtura AgroSolutions business (CAS Acquisition), and the completed acquisition of MacDermid Holdings, LLC (MacDermid Acquisition) on October 31, 2013.
- Related Financings: The pro forma statements also reflect financings related to the aforementioned acquisitions.
Guidance, Outlook, and Risks
Management explicitly states that there can be no assurance that the proposed Arysta Acquisition will close, be completed in the anticipated time frame, or be completed on the terms currently anticipated. The filing provides no specific forward-looking guidance on revenue or earnings growth, relying instead on the historical and pro forma data provided in the exhibits.
Investor Verification Checklist
- Verify the specific revenue, net income, and cash flow figures for Arysta in Exhibit 99.2 and Exhibit 99.3.
- Review the unaudited pro forma combined consolidated balance sheets and statements of operations in Exhibit 99.4 to understand the financial impact of the proposed acquisitions.
- Confirm the status of closing conditions for the $3.51 billion Arysta Acquisition.
- Assess the debt levels and liquidity position of the combined entity as presented in the pro forma statements.